ServiceTitan's stock dropped 30% after reporting Q2 2027 results that revealed slower revenue growth and unexpected revenue recognition timing issues related to its AI Max product. The company also replaced its chief revenue officer amid these challenges. This sharp decline erased over $2 billion in market value and led to a shareholder rights firm launching an investigation into potential transparency and securities law violations. Investors who suffered losses are encouraged to participate in the investigation as the company navigates these financial and leadership hurdles.
ServiceTitan's recent 30% stock drop followed Q2 2027 results revealing slower revenue growth and revenue timing issues. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 02, 2026 01:02 WIB: out of 150 priced US tech stocks, 126 rose and 24 fell. Notable movers include INFY at USD 11.48 with 3% Sell / 97% Buy order activity, CRDO at USD 207.74 with 75% Sell / 25% Buy, and CDW at USD 136.63 with a typical hold time of 60 days.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
